Literature DB >> 32044451

Key steps in vaccine development.

Peter L Stern1.   

Abstract

OBJECTIVE: The goal of a vaccine is to prime the immune response so the immune memory can facilitate a rapid response to adequately control the pathogen on natural infection and prevent disease manifestation. This article reviews the main elements that provide for the development of safe and effective vaccines. DATA SOURCES: Literature covering target pathogen epidemiology, the key aspects of the functioning immune response underwriting target antigen selection, optimal vaccine formulation, preclinical and clinical trial studies necessary to deliver safe and efficacious immunization. STUDY SELECTIONS: Whole live, inactivated, attenuated, or partial fractionated organism-based vaccines are discussed in respect of the balance of reactogenicity and immunogenicity. The use of adjuvants to compensate for reduced immunogenicity is described. The requirements from preclinical studies, including establishing a proof of principle in animal models, the design of clinical trials with healthy volunteers that lead to licensure and beyond are reviewed.
RESULTS: The 3 vaccine development phases, preclinical, clinical, and post-licensure, integrate the requirements to ensure safety, immunogenicity, and efficacy in the final licensed product. Continuing monitoring of efficacy and safety in the immunized populations is essential to sustain confidence in vaccination programs.
CONCLUSION: In an era of increasing vaccine hesitancy, the need for a better and widespread understanding of how immunization acts to counteract the continuing and changing risks from the pathogenic world is required. This demands a societal responsibility for obligate education on the benefits of vaccination, which as a medical intervention has saved more lives than any other procedure.
Copyright © 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32044451     DOI: 10.1016/j.anai.2020.01.025

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  14 in total

1.  Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile.

Authors:  Susan M Bueno; Katia Abarca; Pablo A González; Nicolás M S Gálvez; Jorge A Soto; Luisa F Duarte; Bárbara M Schultz; Gaspar A Pacheco; Liliana A González; Yaneisi Vázquez; Mariana Ríos; Felipe Melo-González; Daniela Rivera-Pérez; Carolina Iturriaga; Marcela Urzúa; Angélica Domínguez; Catalina A Andrade; Roslye V Berríos-Rojas; Gisela Canedo-Marroquín; Camila Covián; Daniela Moreno-Tapia; Farides Saavedra; Omar P Vallejos; Paulina Donato; Pilar Espinoza; Daniela Fuentes; Marcela González; Paula Guzmán; Paula Muñoz Venturelli; Carlos M Pérez; Marcela Potin; Álvaro Rojas; Rodrigo A Fasce; Jorge Fernández; Judith Mora; Eugenio Ramírez; Aracelly Gaete-Argel; Aarón Oyarzún-Arrau; Fernando Valiente-Echeverría; Ricardo Soto-Rifo; Daniela Weiskopf; Alessandro Sette; Gang Zeng; Weining Meng; José V González-Aramundiz; Alexis M Kalergis
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

2.  Who is running faster, the virus or the vaccine?

Authors:  Han Dai; Jie Han; Eric Lichtfouse
Journal:  Environ Chem Lett       Date:  2020-10-15       Impact factor: 9.027

3.  Primary prevention: Vaccines and the allergist-immunologist's role.

Authors:  Mitchell H Grayson
Journal:  Ann Allergy Asthma Immunol       Date:  2020-07       Impact factor: 6.347

4.  Development of a Broadly Protective, Self-Adjuvanting Subunit Vaccine to Prevent Infections by Pseudomonas aeruginosa.

Authors:  Sayan Das; Debaki R Howlader; Qi Zheng; Siva Sai Kumar Ratnakaram; Sean K Whittier; Ti Lu; Johnathan D Keith; William D Picking; Susan E Birket; Wendy L Picking
Journal:  Front Immunol       Date:  2020-11-17       Impact factor: 7.561

Review 5.  Coronavirus disease 2019 vaccine: An overview of the progression and current use.

Authors:  Safiye Gocer; Can Turk; Sukru Volkan Ozguven; Mehmet Doganay
Journal:  North Clin Istanb       Date:  2021-10-18

6.  Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice.

Authors:  Junfei Wei; Venkatesh L Hegde; Ananta V Yanamandra; Madison P O'Hara; Brian Keegan; Kathryn M Jones; Ulrich Strych; Maria Elena Bottazzi; Bin Zhan; K Jagannadha Sastry; Peter J Hotez
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561

7.  Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3-12 Years Old.

Authors:  Khaled Greish; Abdulla Alawadhi; Ahmed Jaradat; Amer Almarabheh; Marwa AlMadhi; Jaleela Jawad; Basma Alsaffar; Ejlal Alalawi; Adel Alsayyad; Afaf Merza; Batool Alalawi; Donia Qayed; Ahmed Humaidan; Manaf Al Qahtani
Journal:  Vaccines (Basel)       Date:  2022-04-11

8.  Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt.

Authors:  Amani A Saleh; Mohamed A Saad; Islam Ryan; Magdy Amin; Mohamed I Shindy; Wael A Hassan; Mahmoud Samir; Ayman A Khattab; Sherein S Abdelgayed; Mohamed G Seadawy; Hossam M Fahmy; Khaled Amer
Journal:  Antib Ther       Date:  2021-06-25

Review 9.  Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.

Authors:  Katie L Flanagan; Emma Best; Nigel W Crawford; Michelle Giles; Archana Koirala; Kristine Macartney; Fiona Russell; Benjamin W Teh; Sophie Ch Wen
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

Review 10.  Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.

Authors:  Asghar Abdoli; Reza Aalizadeh; Hossein Aminianfar; Zahra Kianmehr; Ali Teimoori; Ebrahim Azimi; Nabbi Emamipour; Marzieh Eghtedardoost; Vahid Siavashi; Hamidreza Jamshidi; Mohammadreza Hosseinpour; Mohammad Taqavian; Hasan Jalili
Journal:  Rev Med Virol       Date:  2021-10-26       Impact factor: 11.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.